Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective reduced by JPMorgan Chase & Co. from $37.00 to $20.00 in a report issued on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the company. Leerink Partners upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their target price for the company from $40.00 to $34.00 in a research note on Thursday. HC Wainwright dropped their price target on Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Scotiabank lowered their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th. Finally, Bank of America cut their target price on Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating on the stock in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Agios Pharmaceuticals Stock Up 2.7%

AGIO stock traded up $0.67 during trading on Friday, hitting $25.24. 3,635,243 shares of the company’s stock traded hands, compared to its average volume of 1,840,001. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -3.61 and a beta of 0.89. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $62.45. The stock has a fifty day moving average price of $39.91 and a two-hundred day moving average price of $36.79.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. During the same period last year, the firm posted $16.22 EPS. The company’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, equities research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at $1,245,399.90. This represents a 9.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the transaction, the insider owned 61,727 shares in the company, valued at approximately $2,711,049.84. This trade represents a 5.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 16,099 shares of company stock worth $620,092. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning grew its stake in shares of Agios Pharmaceuticals by 2.2% in the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 280 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 320 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 499 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Agios Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock worth $4,393,000 after buying an additional 512 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in Agios Pharmaceuticals by 0.3% in the second quarter. Nordea Investment Management AB now owns 224,746 shares of the biopharmaceutical company’s stock worth $7,520,000 after buying an additional 573 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.